Ipsen : to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference -Today at 11:53 am

Studies Demonstrate Ipsen's Ongoing Commitment to Innovation and Improving Patient Care
in Neuroendocrine Tumors


Paris , 28 February 2019 - Ipsen today announced that...

Related Keywords

France ,Northwestern University ,Illinois ,United States ,Spain ,Chicago ,Ireland ,Barcelona ,Comunidad Autonoma De Cataluna ,Ipsen Euronext ,Daphnet Adelman ,Sotirios Stergiopoulos ,European Union ,European Neuroendocrine Tumor Society ,Satisfaction Survey Of Administration Modes For Long ,Studies Demonstrate Ipsen ,Ongoing Commitment ,Improving Patient ,Neuroendocrine Tumors ,Annual Conference ,Chief Medical Officer ,Clinical Nurse Specialist ,Day Dosing Interval ,For Patients With Pancreatic ,Midgut Neuroendocrine Tumours ,Satisfaction Survey ,Administration Modes ,Somatostatin Analog ,Neuroendocrine Tumuors ,Cognitive Interviews With Patients ,Carcinoid Syndrome Diarrhea ,Patient Experience Outcomes ,Systematic Literature Review ,Differential Diagnosis ,Controlled Carcinoid Syndrome ,Neuroendocrine Tumours ,Long Term Treatment ,Telotristat Ethyl ,Carcinoid Syndrome ,Preliminary Efficacy ,Somatostatin Receptor ,Positive Neuroendocrine Tumours ,Markets ,